Gil Melmed, MD

Gil Melmed, MD, is affiliated with Cedars-Sinai Inflammatory Bowel Disease Center.

Articles by Gil Melmed, MD

Real-World Data Favor Risankizumab for Long-Term Persistence in Crohn's Disease

May 4th 2026

Gil Melmed, MD, breaks down real-world data showing risankizumab has the lowest switch rates in Crohn’s over 24 months, highlighting strong persistence vs other biologics.

Latest Updated Articles

Gil Melmed, MD

Articles by Gil Melmed, MD

Real-World Data Favor Risankizumab for Long-Term Persistence in Crohn's Disease

Latest Updated Articles

Trending on HCPLive

How Dermatology PAs Can Master Rapid Diagnostic Recognition

STAT6, ITK Inhibitors, IL-31, & IL-18 Headline Burgeoning Pipeline in Atopic Dermatitis, with David Rosmarin, MD

Emerging Evidence in Atopic Dermatitis Management, With Harrison Nguyen, MD, MBA, MPH

Managing FCS: LPL-Targeted Therapy, Drug Rationalization, and Atherosclerosis Risk

Diagnosing FCS Without Genetic Confirmation: Scoring Tools and Referral Gaps